• Avricore has been focused on the development of a network of POC analyzers running on its HealthTab software platform in community pharmacy
• So far, its platform can check up to 27 health markers, screen diabetes, and test Covid-19
• With multiple revenue streams, a key selling point for Avricore remains its commitment to patient health and convenience
• Through its innovations and forging the right partnerships, Avricore is getting closer to consumers and presenting even more possibilities for its HealthTab platform

At the start of 2021, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) set out to achieve four main milestones- the Abbott agreement, the Shoppers agreement, the HeathTab(TM) Pilot, and the HealthTab Rollout. As of May 31, 2021, the company had already signed a deal with Abbott to expand the distribution of its Afnion 2 analyzer in pharmacies, while on June 3, Shoppers signed an agreement to stock HealthTab for diabetes screening in 11 different locations, bringing its services closer to patients (https://ibn.fm/vFITf).

Since its inception, Avricore has been driven by the development of a network of point-of-care (“POC”) analyzers that run on the company’s HealthTab software in community pharmacies, workplaces, and rural areas (https://ibn.fm/TrrRA).

The company has recognized an opportunity and capitalizes on established consumer trends, technology advancements, health policy, and industry changes, to solve a business headache while also meeting a significant market opportunity. All this is built on the company’s HealthTab platform. As it works towards the HealthTab rollout, Avricore is implementing its decisions from a point of information and knowing its platform’s potential.

So far, HealthTab can check up to 27 health markers, screen diabetes, and conduct rapid Covid-19 testing. It also offers convenience, with analyses taking less than 10 minutes. Most importantly, it is a platform that prioritizes safety and confidentiality, given that the consumer is in control of their data, ultimately choosing whom they can share it with (https://ibn.fm/FTSN1).

Avricore has several revenue streams, including equipment leasing, data, consumables, screening tests, and application programming interface (“API”) integration. However, its primary selling point is its commitment to patients, primarily through its HealthTab platform.

“What HealthTab does is it creates a space where a patient can take direct agency over their health. They can walk into any pharmacy, they can ask that question, and they can get information that they can act on now,” noted Hector Bremner, the chief executive officer (“CEO”) of Avricore (https://ibn.fm/dBYXP).

The milestones achieved with HealthTab so far are significant. More so, they highlight the endless possibilities that the platform has regarding the diagnosis of various chronic diseases, bacteria, and viruses. This is further evidenced by the company’s recent moves and executive decisions. Its expansion of POC medical condition testing to Canada’s west coast and the planned HealthTab rollout are a testament to what the platform is capable of, Avricore’s potential going forward, and the company’s commitment to patients.

Avricore is at the forefront in the POC diagnostics space and remains committed to becoming the world’s largest health diagnostics company. With consistent innovation and forging the right partnerships with strategic players in the healthcare sector, Avricore is getting closer to the consumers and presenting even more possibilities with its HealthTab platform.

For more information, visit the company’s website at www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.